Loading
Life sciences · Journal article
Clinical Cancer Research · October 21, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Purpose: COPE evaluated serial circulating tumor DNA (ctDNA) profiling with molecular tumor board (MTB) review during first-line therapy for advanced non–small cell lung cancer (NSCLC). Experimental Design: COPE was a multicenter, randomized (2:1), noncomparative phase II trial. Arm A underwent serial plasma profiling with every report reviewed at a weekly virtual MTB; Arm B received standard management. The primary endpoint was 18-month overall survival (OS) in Arm A versus a prespecified 40% historical benchmark; no between-arm comparison was planned. Results: Among 176 patients, 117 were assigned to Arm A and 59 to Arm B. Eighteen-month OS was 53.8% (95% CI, 44.3–62.5) and 65.7% (95% CI, 52.0–76.3), respectively. Baseline plasma profiling provided contributory information in 32 of 35 patients with noncontributory or unavailable tissue, increasing genotyping success from 69% to 97%. Paired baseline and early on-treatment samples were available in 90 patients (median, 21 days; range, 19–64). ctDNA clearance was associated with higher objective response rate (83% vs. 52%), longer progression-free survival (22.9 vs. 5.4 months; P<0.001), and longer OS (not reached vs. 17.1 months; P=0.004) than persistent detection. Conclusions: Serial ctDNA profiling with weekly MTB review was operationally feasible and complemented tissue genotyping. Clinical benefit was not demonstrated; early ctDNA kinetics require validation in interventional trials.